logo

For the Inventor, By the Inventor

Shanghai, China

Xuemei Wang

This inventor holds 7 USPTO granted patents and 1 published patent application and 3 EPO patents. Top assignees: Hoffmann-La Roche Inc., Semiconductor Manufacturing International (Beijing) Corporation, Semiconductor Manufacturing International (Shanghai) Corporation. Active years: 2021-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xuemei Wang. Retrieved from https://idiyas.com/inventor/xuemei-wang-k0xqtiqe

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 7 

% Patents Active = 85.7

 

Average Co-Inventor Count = 3.8

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:

goldMedal6 out of 5,026 
 
Hoffmann-La Roche Inc.
 patents
silverMedal1 out of 950 
 
Semiconductor Manufacturing International (Beijing) Corporation
 patents
bronzeMedal1 out of 1,755 
 
Semiconductor Manufacturing International (Shanghai) Corporation
 patents
where one patent can have more than one assignee

Years Active: 2021-2026

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents
1. 12655153 - Solid forms of a HBV core protein allosteric modifier (2026-06-16),
2. 12012421 - Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate (2024-06-18),
3. 12012420 - Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate (2024-06-18),
4. 11873302 - Solid forms of a compound of HBV core protein allosteric modifier (2024-01-16),
5. 11658239 - Semiconductor device and fabrication method thereof (2023-05-23),
6. 11230559 - Solid forms of [(1 S)-1 -[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-D]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-Yl]proptl] acetate (2022-01-25),
7. 11142534 - Process for the preparation of 3-substituted 5-amino-6H-thiazolo[4,5-d]pyrimidine-2,7-dione compounds (2021-10-12),

Title: Xuemei Wang: An Innovative Mind in Pharmaceutical Development

Introduction

Xuemei Wang is an accomplished inventor based in Shanghai, China. He holds a notable six patents, showcasing his significant contributions to the field of pharmaceutical innovations. His work focuses on developing novel solid forms of compounds that have potential therapeutic applications.

Latest Patents

Wang's latest patents include novel solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate. These innovative compounds may act as TLR7 agnoists, providing promising avenues for the treatment or prophylaxis of viral diseases, particularly those related to HBV infection.

Career Highlights

Throughout his career, Xuemei Wang has partnered with several prestigious companies. Notably, he has worked at Hoffmann-La Roche Inc. and Semiconductor Manufacturing International Corporation, where he gained valuable experience in the pharmaceutical and semiconductor industries.

Collaborations

Wang has collaborated with notable figures in his field, including Jing Xiong and Katja Grosse-Sender. These partnerships have contributed to the advancement of his research and innovations.

Conclusion

Xuemei Wang exemplifies a dedicated inventor with a focus on developing novel pharmaceutical solutions. His patents and collaboration with esteemed companies illustrate his commitment to enhancing medical treatments, particularly in combating viral diseases. With his expertise, Wang continues to make strides in the realm of pharmaceutical inventions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…